GSK Set For Breo Launch, But Access Will Require Time
GlaxoSmithKline will launch its once-daily COPD treatment Breo in the U.S. in October, Senior VP-Respiratory Jorge Bartolome said in an interview. The company will market Breo as the first once-daily ICS/LABA combination offering 24-hour lung function improvement. But already some payers are denying coverage.
You may also be interested in...
GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.
With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.